Universal Health Services 'B'

With UHS stock trading at a discount, we examine its growth drivers and challenges to determine if it presents a strong investment opportunity for investors at this time.» Mehr auf zacks.com

Goldman Sachs analyst Jamie Perse downgraded Tenet Healthcare to Neutral from Buy with a price target of $140, down from $196. Amid rising policy uncertainty, with a wide range of potential outcomes, Goldman is taking a more cautious view on healthcare providers, the analyst tells investors in a research note. With this view, the firm downgraded hospitals Tenet (THC) and Universal Health (UHS) to Neutral while upgrading Lifestance Health Group (LFST) to Buy, where it believes the company is more insulated from policy risk. For Tenet, the analyst sees policy risk "taking center stage" and likely leaving shares range bound until policy outcomes are better defined, reflected in out year estimates, and in the stock's valuation.» Mehr auf thefly.com

Goldman Sachs upgraded LifeStance to Buy from Neutral with a $10 price target. Amid rising policy uncertainty, with a wide range of potential outcomes, Goldman is taking a more cautious view on healthcare providers, the analyst tells investors in a research note. With this view, the firm downgraded hospitals Tenet (THC) and Universal Health (UHS) to Neutral while upgrading Lifestance Health Group (LFST) to Buy, where it believes the company is more insulated from policy risk. The analyst believes LifeStance's continued operational execution will continue in 2025, and on an organic basis, Goldman's analysis suggests its EBITDA can grow 27% through 2027.» Mehr auf thefly.com